Literature DB >> 20732236

Evaluation of the bovine corneal opacity-permeability assay as an in vitro alternative to the Draize eye irritation test.

P Vanparys1, G Deknudt, M Sysmans, G Teuns, W Coussement, H Van Cauteren.   

Abstract

The bovine corneal opacity-permeability assay (BCO-P) was evaluated as an in vitro alternative test model for the Draize eye irritancy test. Fifty pharmaceutical and commercially available compounds were tested in the BCO-P assay. The compounds were selected on the basis of their in vivo irritancy potential as determined in previous Draize tests. Liquids as well as solids were tested. Corneal opacity and permeability were measured to determine ocular irritation potential. When two irritancy classifications (non-irritant and irritant) were considered, 96% of the tested chemicals were classified correctly. A 72% concordance was obtained when four irritancy classifications (non-irritant, mild, moderate and severe irritant) were considered. Furthermore, all compounds that were severe eye irritants in vivo were equally scored in vitro. The results of this study show that the BCO-P assay is a competent in vitro test system for the prediction of ocular irritation of chemicals. This test model can be used as a first screen to avoid in vivo testing of severe ocular irritants.

Entities:  

Year:  1993        PMID: 20732236     DOI: 10.1016/0887-2333(93)90049-b

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  2 in total

1.  The development of antimicrobial a-AApeptides that suppress proinflammatory immune responses.

Authors:  Shruti Padhee; Christina Smith; Haifan Wu; Yaqiong Li; Namitha Manoj; Qiao Qiao; Zoya Khan; Chuanhai Cao; Hang Yin; Jianfeng Cai
Journal:  Chembiochem       Date:  2014-03-21       Impact factor: 3.164

2.  The mucosal toxicity of different benzalkonium chloride analogues evaluated with an alternative test using slugs.

Authors:  E Adriaens; K Dierckens; T G Bauters; H J Nelis; F van Goethem; P Vanparys; J P Remon
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.